Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
In a landmark decision poised to reshape access to one of the world’s most sought-after medications, Health Canada has granted…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a rapidly emerging biotech startup formerly known as Somite AI, has secured global rights to a clinical-stage Parkinson’s…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
In a landmark decision poised to reshape access to one of the world’s most in-demand medications, Health Canada has granted…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…
Read More
Novo Nordisk Transfers Parkinson’s Cell Therapy to Cellular Intelligence, Signaling New Era for AI-Driven Biopharma
In a significant development for the burgeoning field of cell therapy and artificial intelligence in drug discovery, Cellular Intelligence, a…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The pharmaceutical landscape for diabetes and weight management medications has undergone a significant shift with Health Canada’s authorization of Dr.…
Read More
Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo
Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
Novo Nordisk’s Wegovy Pill Gains UK Approval Amidst Growing Demand and Competitive Landscape
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Novo Nordisk’s oral semaglutide medication, marketed…
Read MoreYOU MAY HAVE MISSED
